Avanos Medical, Inc. (NYSE: AVNS) completed a merger transaction on July 27, 2026, in which all outstanding common stock was exchanged for $25.00 per share in cash. Scott Michael Galovan, the company's Senior Vice President and Chief Financial Officer, had his equity holdings—including common stock, restricted stock units, performance-based units, and stock options—converted into cash payments under the merger agreement terms. The conversion included both vested and unvested equity awards held by the executive.
Key Points
- NYSE: AVNS
- Avanos Medical completed a merger on July 27, 2026, converting all common stock to $25.00 per share in cash
- CFO Galovan's holdings included 135,596 shares of common stock, 86,918 time-based restricted stock units, 96,121 performance-based restricted stock units, and stock options with exercise prices of $13.69 and $15.24
- The merger agreement converted all equity awards into cash payments, with performance-based units eligible for true-up adjustments based on fiscal year 2026 actual performance
Merger Completion and Stock Conversion Terms
The disclosure filed on July 28, 2026, confirms that Avanos Medical's merger became effective on July 27, 2026. According to the merger agreement dated April 13, 2026, each outstanding share of Avanos common stock was converted into the right to receive $25.00 per share in cash, without interest. The transaction involved A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc., a wholly-owned subsidiary of the parent entity. This cash-per-share consideration applied uniformly to all shareholders holding common stock at the effective time of the merger.
Under the terms of the merger agreement, the conversion affected all equity-based compensation instruments held by company insiders, not solely shares of outstanding stock. The agreement specifically addressed the treatment of restricted stock units subject to time-based vesting, restricted stock units subject to performance-based vesting, and employee stock options. Each category of equity received distinct treatment based on its characteristics and vesting schedule, with calculations designed to determine the cash equivalent payable to the executive.
Treatment of CFO Galovan's Time-Based Restricted Stock Units
Scott Galovan held 86,918 restricted stock units subject solely to time-based vesting conditions at the time of the merger. Upon the effective time of the merger, these company time-based restricted stock units (referred to as Company TRSUs in the filing) were canceled immediately. In place of the canceled awards, Galovan became entitled to receive a cash payment calculated by multiplying the $25.00 merger consideration per share by the number of shares the executive would have received had the Company TRSUs vested in full. Tax withholdings applied to the resulting cash amount.
The structure of the time-based RSU conversion ensured that unvested equity awards did not lose value in the transaction. Rather than forfeiting the remaining vesting schedule, the executive received cash compensation reflecting the full value of the underlying shares. This approach is common in merger transactions involving cash consideration, as it preserves the economic value of equity awards while simplifying the transition to the post-merger structure.
Performance-Based Restricted Stock Unit Conversion and True-Up Provisions
Galovan also held 96,121 restricted stock units subject to performance-based vesting conditions (Company PRSUs) at the time of merger. These awards required achievement of specified performance metrics within one-year performance periods to determine the number of shares ultimately vested. The filing indicates that 96,121 shares' worth of Company PRSUs were acquired and then disposed of on July 27, 2026, reflecting the deemed vesting and conversion mechanics under the merger agreement.
The merger agreement provided a multi-tiered treatment for performance-based units. For any one-year performance period completed prior to the merger's effective time, the conversion was calculated using actual performance achievement against metrics. For performance periods in progress as of the effective time—identified in the filing as fiscal year 2026—the payout was determined using the greater of actual achievement or the target level. For any performance periods not yet commenced, the conversion assumed deemed achievement at target level. The filing notes that the reporting person received the aggregate payout of 96,121 Company PRSUs at target performance for fiscal year 2026 within 15 business days of the effective time. However, if actual performance for fiscal year 2026 exceeds target, Galovan will receive an additional true-up payment, with the maximum potential payout from this award capped at 127,534 shares' equivalent. Tax withholdings applied to all cash payments received.
Stock Option Conversion and In-the-Money Calculations
Galovan held two tranches of employee stock options at the time of the merger. The first comprised 69,630 options with an exercise price of $13.69 per share, originally scheduled to vest 30 percent on March 13, 2027, 30 percent on March 13, 2028, and 40 percent on March 13, 2029, with an expiration date of March 13, 2036. The second comprised 21,038 options with an exercise price of $15.24 per share, originally scheduled to vest 30 percent on March 7, 2026, 30 percent on March 7, 2027, and 40 percent on March 7, 2028, with an expiration date of March 7, 2035.
Pursuant to the merger agreement, all stock options were canceled immediately prior to the effective time. In exchange, option holders received cash in an amount determined by multiplying the excess of the $25.00 merger consideration minus the applicable exercise price by the number of shares the executive would have received upon full vesting of the option. Because both exercise prices ($13.69 and $15.24) were below the $25.00 merger consideration, both option tranches generated positive intrinsic value and resulted in cash payments to Galovan. Tax withholdings were deducted from these payments. The filing states that company stock options with an exercise price exceeding the merger consideration were canceled for no consideration, exempt from Section 16 reporting requirements under the applicable rules.
Direct Ownership Structure and Filing Mechanics
All of Galovan's securities were held in direct ownership form (rather than indirectly through trusts, partnerships, or other vehicles) according to the filing. The disclosure was filed as a single-person Form 4 submission, as only one reporting person was involved in the transaction. Galovan serves as Senior Vice President and Chief Financial Officer of Avanos Medical, a position that triggers Section 16 reporting obligations under the Securities Exchange Act of 1934.
The filing was signed on July 28, 2026—the day after the merger's effective date—by John S. Fischer, acting as attorney-in-fact for Galovan. This delegation of signature authority is permissible under SEC rules and is common practice for executive officers managing multiple regulatory filings. The document contains all required tables detailing both non-derivative securities (common stock and restricted stock units) and derivative securities (employee stock options) acquired, disposed of, or beneficially owned following the reported transactions.
Reporting Obligations and Section 16 Implications
The Form 4 filing reflects changes in beneficial ownership triggered by the merger's effective date. Before the transaction, Galovan directly owned 135,596 shares of common stock. These shares, along with the time-based and performance-based RSUs and stock options, were all outstanding equity interests subject to Section 16 reporting requirements. The merger converted all these interests into cash settlement rights on a single date, eliminating future beneficial ownership of Avanos common stock or derivatives for the reporting person.
The filing indicates that Galovan no longer holds beneficial ownership of any common stock or derivative securities of Avanos Medical following the merger's completion. All previously held equity awards—whether vested, unvesting, or subject to performance conditions—have been converted to cash payment obligations under the merger agreement. This conversion completes the executive's transition out of direct equity ownership in the company as a result of the merger transaction.
Merger Agreement Background and Timeline
The merger agreement governing these conversions was dated April 13, 2026, approximately three and a half months before the effective time of July 27, 2026. The delay between signing and closing allowed time for regulatory approvals, shareholder consent, and closing condition satisfaction. The agreement established the uniform $25.00 per share cash consideration and outlined the detailed mechanics for converting various categories of equity awards held by company insiders and employees.
The transaction involved two entities on the acquirer's side: A-AV Holdco I, Inc., and A-AV MergerSub, Inc., with MergerSub functioning as the direct merger vehicle. This two-entity structure is typical in acquisition transactions, allowing the parent company to organize the acquisition through a subsidiary while maintaining separate corporate structures. Avanos Medical shareholders and optionholders received cash consideration in accordance with their holdings and the terms outlined in the merger agreement.
Cash Payment Timing and Tax Withholding Procedures
The filing discloses that performance-based restricted stock unit payouts were delivered to Galovan at or within 15 business days following the merger's effective time. This timeframe aligns with standard merger closing procedures for settling equity awards on an accelerated basis. The settlement of time-based RSUs, stock options, and other equity awards would have followed similar timelines, though the filing does not specify exact payment dates for each category.
All cash payments described in the filing were subject to applicable tax withholdings. The merger agreement's conversion formulas calculated the gross cash payable before tax deductions. For restricted stock units, withholdings reduced the merger consideration multiplied by the number of vested or deemed-vested shares. For stock options, withholdings reduced the spread calculation (merger consideration minus exercise price times the number of shares). The actual net cash received by Galovan for each award category would reflect these tax adjustments, though the filing does not separately itemize the withholding amounts.
Potential Performance-Based Unit True-Up Adjustment
A significant feature disclosed in the filing is the potential true-up adjustment for the fiscal year 2026 performance-based restricted stock units. Galovan received an initial payout of 96,121 shares' equivalent at target performance levels immediately following the merger. However, the merger agreement permits an additional true-up payment if actual performance for fiscal year 2026 exceeds the target level originally used in the conversion calculation. The maximum aggregate number of Company PRSUs Galovan could earn based on actual fiscal year 2026 performance is stated as 127,534 shares' worth of consideration—a potential additional value of approximately 31,413 shares equivalent if maximum performance is achieved.
The true-up provision reflects an attempt to balance certainty in deal timing with equity plan fairness. Because the merger closed before the complete fiscal year 2026 performance period concluded, the agreement incorporated a mechanism to pay executives based on actual results once the year ended and performance metrics could be finalized. This arrangement prevents executives from losing upside if performance exceeds expectations, while also preventing additional cash outlays if performance falls short of target. The filing does not indicate a timeline for the true-up adjustment, only that it will be paid if fiscal 2026 actual performance exceeds target.



Please wait processing your request...